We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection.
- Authors
Antepowicz, Agata; Habib, Omar; Kirsebom, Freja; Johansson, Cecilia; Gill, Deborah R.; Hyde, Stephen C.
- Abstract
Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis is the only approved treatment modality but is costly and only offered to select vulnerable populations. Here, we investigated gene delivery approaches via recombinant adeno-associated virus (rAAV2/8) and simian immunodeficiency virus (rSIV.F/HN) vectors to achieve sustained in vivo production of palivizumab in a murine model. Delivery of palivizumab-expressing vectors 28 days prior to RSV challenge resulted in complete protection from RSV-induced weight loss. This approach offers prophylaxis against RSV infection, allowing for wider use and reduction in treatment costs in vulnerable populations.
- Subjects
LENTIVIRUSES; PALIVIZUMAB; RESPIRATORY syncytial virus; GENE delivery techniques; WEIGHT loss
- Publication
Scientific Reports, 2021, Vol 11, Issue 1, p1
- ISSN
2045-2322
- Publication type
Article
- DOI
10.1038/s41598-021-95150-z